Evidence map›Paper›PMID 38947034›Full record

ArticleResearch square2024

Treatment with lipoxin A 4 improves influenza A infection outcome through macrophage reprogramming, anti-inflammatory and pro-resolutive responses.

Flavia Rago, Eliza Mathias Melo, Leigh M Miller, Alexis M Duray, Franciel Batista Felix, Juliana Priscila Vago, Ana Paula Faria Gonçalves, Ana Luiza Pessoa Mendonça Angelo, Giovanni D Cassali, Monica Gaetano and 6 more

Abstract readPreprint
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Flavia RagoUMPC Children's Hospital of Pittsburgh.
Eliza Mathias MeloUniversidade Federal de Minas Gerais.
Leigh M MillerUMPC Children's Hospital of Pittsburgh.
Alexis M DurayUMPC Children's Hospital of Pittsburgh.
Franciel Batista FelixUniversidade Federal de Minas Gerais.
Juliana Priscila VagoUniversidade Federal de Minas Gerais.
Ana Paula Faria GonçalvesOswaldo Cruz Foundation (FIOCRUZ-Minas).
Ana Luiza Pessoa Mendonça AngeloOswaldo Cruz Foundation (FIOCRUZ-Minas).
Giovanni D CassaliUniversidade Federal de Minas Gerais.
Monica GaetanoUniversity College Dublin.
Eoin BrennanUniversity College Dublin.
Benjamin OwenUniversity College Dublin.
Patrick GuiryUniversity College Dublin.
Catherine GodsonUniversity College Dublin.
John F AlcornUMPC Children's Hospital of Pittsburgh.
Mauro Martins TeixeiraUniversidade Federal de Minas Gerais.

Funding

Influenza A Inhibits TH17 Host Defense Against Bacterial PneumoniaR01HL107380 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ALCORN, JOHN F · 2012 to 2024
$5.4M
NHLBI NIH HHS R01 HL107380
6 · The paper itself

Abstract

Objective and design: Here, we evaluated whether a synthetic lipoxin mimetic, designated AT-01-KG, would improve the course of influenza A infection in a murine model. Treatment: Mice were infected with influenza A/H1N1 and treated with AT-01-KG (1.7 mg/kg/day, i.p.) at day 3 post-infection. Methods: Mortality rate was assessed up to day 21 and inflammatory parameters were assessed at days 5 and 7. Results: AT-01-KG attenuated mortality, reducing leukocyte infiltration and lung damage at day 5 and day 7 post-infection. AT-01-KG is a Formyl Peptide Receptor 2 (designated FPR2/3 in mice) agonist, and the protective responses were not observed in FPR2/3 Conclusions: Therefore, treatment with a lipoxin A

Indexed as

InflammationInfluenza APneumoniaPro-resolving mediatorsResolutionRespiratory Infection

Identifiers

PMID38947034
PMCPMC11213203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.